Valneva (NASDAQ:VALN) Upgraded at Wall Street Zen

Key Points

• Valneva has been upgraded to a "hold" rating by Wall Street Zen, reflecting a positive shift in the company's stock outlook.
• Hedge funds and institutional investors have been active in Valneva, with several new positions taken, bringing their ownership to 11.39%.
• For the last quarter, Valneva reported a revenue of $54.84 million, exceeding analysts' expectations of $46.28 million, with an earnings per share of ($0.16).

Wall Street Zen upgraded shares of Valneva (NASDAQ:VALN - Free Report) to a hold rating in a report released on Saturday morning.

Several other research firms have also recently weighed in on VALN. Jefferies Financial Group set a $14.00 price target on shares of Valneva and gave the company a "buy" rating in a report on Monday, August 25th. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Valneva in a report on Monday, August 25th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $15.00.

Valneva Trading Up 1.7%

NASDAQ VALN traded up $0.16 during trading on Friday, reaching $9.09. 37,052 shares of the stock traded hands, compared to its average volume of 70,476. The firm has a market cap of $780.67 million, a price-to-earnings ratio of -9.21 and a beta of 1.79. The stock's 50-day moving average price is $8.15 and its 200 day moving average price is $7.09. The company has a quick ratio of 1.77, a current ratio of 2.27 and a debt-to-equity ratio of 0.66. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $12.25.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The firm had revenue of $54.84 million during the quarter, compared to analysts' expectations of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. Analysts predict that Valneva will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently bought and sold shares of the business. Marex Group plc bought a new position in Valneva during the second quarter worth about $64,000. GAMMA Investing LLC bought a new position in Valneva during the first quarter worth about $94,000. Finally, Frazier Life Sciences Management L.P. bought a new position in shares of Valneva in the second quarter valued at about $8,240,000. Institutional investors own 11.39% of the company's stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.